950604-54-3

Upstream product

• 950605-56-8 2-[2-(5-bromothiophen-2-yl)propan-2-yl]-5-cyclopropyl-1,3,4-oxadiazole 
• 64-04-0 phenethylamine 
• 950605-55-7 2-cyclopropyl-5-[2-(thiophen-2-yl)propan-2-yl]-1,3,4-oxadiazole 
• 950605-40-0 N'-[2-methyl-2-(thiophen-2-yl)propanoyl]cyclopropanecarbohydrazide 
• 880166-34-7 2-methyl-2-(thiophen-2-yl)-propanehydrazide 

Downstream Products

• 950663-91-9 5-{1-[cyclopropyl-4-(2-phenylethyl)-4H-1,2,4-triazol-3-yl]-1-methylethyl}thiophene-2-carbonitrile 
• 950607-59-7 5-{1-[cyclopropyl-4-(2-phenylethyl)-4H-1,2,4-triazol-3-yl]-1-methylethyl}thiophene-2-carbonitrile hydrochloride 

Relevant academic research and scientific papers

Discovery and biological evaluation of potent and orally active human 11β-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes mellitus

We synthesized and evaluated novel 5-[2-(thiophen-2-yl)propan-2-yl]-4H-1,2,4-triazole derivatives as 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors. Optimization of the thiophene ring and the substituents on the 1,2,4-triazole ring produced

TRIAZOLE DERIVATIVE OR SALT THEREOF

[Problem] To provide a compound which may be used in treating diseases in which 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is concerned, especially diabetes and insulin resistance. [Means for Solution] It was found that a triazole derivative or a pharmaceutically acceptable salt thereof, in which the 3-position of triazole ring is substituted with a trisubstituted methyl group and the 5-position is substituted with a lower alkyl, cycloalkyl or the like, has a strong 11β-HSD1-inhibitory activity. In addition, since the triazole derivative of the present invention shows excellent blood glucose-lowering action, it may be used in the treatment of diabetes and insulin resistance.